About the Company
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $EXEL News
Exelixis: With Patent Litigation Decision Due Soon, There Are Options
Exelixis successfully implements Farallon's restructuring suggestions. Multiple billions of potential revenue are at stake.
Buy Rating Affirmed for Exelixis Amid Solid Revenue and Strategic Growth Initiatives
Begin your TipRanks Premium journey today. Exelixis (EXEL) Company Description: Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of ...
Exelixis (EXEL) Shares Cross Below 200 DMA
In trading on Wednesday, shares of Exelixis Inc (Symbol: EXEL) crossed below their 200 day moving average of $21.91, changing hands as low as $20.69 per share. Exelixis Inc shares are currently ...
Exelixis down 7% as Q1 financial results disappoint
Exelixis (NASDAQ:EXEL) is down ~7% in after-hours trading Wednesday after posting Q1 results that missed on both lines.
Hold Rating on Exelixis: Analyzing Q1 Revenue Shortfalls and Pipeline Progress
Andrew Berens, an analyst from Leerink Partners, maintained the Hold rating on Exelixis (EXEL – Research Report). The associated price ...
Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2024, provided an update on progress toward achieving key corporate objectives, and detailed its recent and ...
Institutional investors in Exelixis, Inc. (NASDAQ:EXEL) lost 3.8% last week but have reaped the benefits of longer-term growth
However, on some occasions too much power is concentrated within this group. Our most recent data indicates that insiders own some shares in Exelixis, Inc.. It is a pretty big company, so it is ...
Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2024, provided an update on progress toward achieving key corporate objectives, and detailed its recent and ...
Loading the latest forecasts...